Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$1.01 CAD
Change Today -0.05 / -4.72%
Volume 20.2K
BLU On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt
As of 4:10 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

bellus health inc (BLU) Snapshot

Open
C$1.07
Previous Close
C$1.06
Day High
C$1.10
Day Low
C$1.01
52 Week High
09/2/14 - C$1.80
52 Week Low
08/24/15 - C$0.76
Market Cap
47.9M
Average Volume 10 Days
101.9K
EPS TTM
C$-0.30
Shares Outstanding
47.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BELLUS HEALTH INC (BLU)

Related News

No related news articles were found.

bellus health inc (BLU) Related Businessweek News

No Related Businessweek News Found

bellus health inc (BLU) Details

BELLUS Health Inc., together with its subsidiaries, focuses on the research and development of pharmaceutical drug candidates. The company’s lead program is KIACTA, which is in Phase III clinical trial for the treatment of AA amyloidosis. It is also developing KIACTA for the treatment of chronic sarcoidosis. The company’s clinical stage drug candidate is Shigamab, a monoclonal antibody therapy for the treatment of hemolytic uremic syndrome caused to Shiga toxin-producing E. coli, as well as has a research project to identify drug candidates for the treatment of AL amyloidosis. It has a strategic partnership with Auven Therapeutics for the development of KIACTA and Pharmascience Inc. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

8 Employees
Last Reported Date: 02/27/15
Founded in 1993

bellus health inc (BLU) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$319.0K
Vice President of Finance
Total Annual Compensation: C$172.4K
Senior Vice President of Drug Development
Total Annual Compensation: C$325.0K
Vice President of Business Development
Total Annual Compensation: C$176.8K
Compensation as of Fiscal Year 2014.

bellus health inc (BLU) Key Developments

BELLUS Health Inc. Announces Consolidated Earnings Results for the Second Quarter Ended June 30, 2015; Narrows Timelines for the Phase III Study for KIACTA

BELLUS Health Inc. announced consolidated earnings results for the second quarter ended June 30, 2015. For the quarter, the company announced revenues of CAD 592,000 compared to CAD 420,000 for the same period a year ago. Net loss for the period was CAD 433,000 compared to CAD 768,000 for the same period a year ago. Net loss attributable to shareholders of the company was CAD 426,000 compared to CAD 737,000 for the same period a year ago. Basic and diluted loss per share was CAD 0.01 compared to CAD 0.02 for the same period year ago. Increase in revenue is attributable to higher revenue recognized for accounting purposes in 2015 in relation to the service agreement with Auven Therapeutics for KIACTA. The company narrowed timelines for the Phase III Confirmatory Study for KIACTA in AA amyloidosis. To date, approximately 85% of the required events to complete the Phase III Confirmatory Study for KIACTA have occurred. The KIACTA Phase III Confirmatory Study is an event-driven trial that will conclude when 120 patients have experienced an event linked to the deterioration of kidney function. Based on the event rate, the company anticipates the study will meet the 120 events required to complete the trial by the end of the first quarter of 2016. Concurrently, management expects that top-line data from the study, which is designed to confirm the safety and efficacy of KIACTA in preventing renal function decline in patients diagnosed with AA amyloidosis, will be available in the middle of 2016. During the second quarter of 2015, the KIACTA Phase III Confirmatory Study continued to progress, following patient enrollment completion in January 2015. A total of 261 patients are participating in the study. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients diagnosed with AA amyloidosis, an orphan indication resulting in renal dysfunction that often leads to dialysis and death. As part of the Phase III Confirmatory Study, there are periodic meetings of the Data Safety Monitoring Board (DSMB), which independently assesses the safety of KIACTA throughout the study. Based on its last review in July 2015, the DSMB recommended that the study continue as per protocol. The company also announced pre-clinical studies are being conducted to evaluate Shigamab in the treatment of Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). A clinical advisory board meeting will be held in September 2015 to discuss the design of the Phase II clinical study protocol. During 2014, in studies performed in collaboration with the Uniformed Services University of the United States Department of Defense, Shigamab was shown to reduce toxicity of Shiga toxin type 2 in a sHUS mouse model, even following delayed treatment, as measured by body weight loss, renal biomarkers and renal histopathology. These results support BELLUS Health's treatment approach of sHUS. Shigamab is a monoclonal antibody therapy being developed for the treatment of sHUS, which principally affects the kidneys and often leads to acute dialysis, and in certain cases chronic kidney disease and death, primarily in children.

BELLUS Health Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015

BELLUS Health Inc. announced earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported loss from operating activities of CAD 256,000 compared to an income from operating activities of CAD 879,000 for the same quarter ended March 31, 2014. Loss before income taxes was CAD 12,000 compared to a loss before income taxes of CAD 708,000 for the same quarter ended March 31, 2014.

Bellus Health Inc. Reports Consolidated Earnings Results for the First Quarter Ended March 31, 2015

BELLUS Health Inc. reported consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s revenues were CAD 786,000 compared to CAD 475,000 a year ago. Net loss attributable to shareholders was CAD 46,000 or CAD 1 per basic and diluted share, compared to CAD 680,000 or CAD 0.01 per basic and diluted share, a year ago. The increase is primarily attributable to sales-based royalty revenue received in 2015 in relation to the VIVIMIND license agreement with FB Health. The increase is also attributable to higher revenue recognized for accounting purposes in 2015 in relation to the service agreement with Auven Therapeutics for KIACTA.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLU:CN C$1.01 CAD -0.05

BLU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $82.35 USD -0.84
Novartis AG SFr.92.50 CHF -2.20
Pfizer Inc $32.22 USD -0.44
View Industry Companies
 

Industry Analysis

BLU

Industry Average

Valuation BLU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.6x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BELLUS HEALTH INC, please visit www.bellushealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.